Recent measures in the U.S., Europe and China show overlapping priorities for peptide quality and dossier development, while the legal pathways remain jurisdiction- and product-specific. For companies filing across regions, a well-structured core chemistry, manufacturing and controls (CMC) package may reduce duplicated preparation, while local requirements still need separate review.
Europe (EMA). The EMA's guideline on synthetic peptides — effective 1 June 2026 — recognises that synthetic peptides sit between small molecules and proteins and need special quality considerations: defined starting-material rationale, synthesis/purification process validation, full control of synthetic-related impurities and degradation products, and thorough characterisation (amino-acid analysis, mass spectrometry, peptide mapping). Crucially, the EMA does not use a fixed amino-acid-length cutoff for classification; it assesses how the product is made (recombinant/cellular → generally a biological). In a landmark April 2026 ruling, the Court of Justice of the EU (CJEU) confirmed that chemically synthesised peptides can follow the generic pathway for reference biological medicines, provided identical qualitative/quantitative composition, same dosage form and demonstrated bioequivalence — a development whose practical effect should be assessed against the final judgment and product-specific facts.
China (NMPA / CDE). China is both tightening its framework and accelerating innovation. In January 2025 the CDE issued a clinical-pharmacology guideline for peptide drugs closely aligned with the FDA's 2023 framework. In September 2025 NMPA published trial GLP-1 RA chemistry guidance. Most importantly, on 16 March 2026 the CDE issued a "common issues" clarification on filing paths for fully chemically-synthesised peptides referenced against fermentation-derived products: no marketed chemical-synthesis equivalent → file as chemical drug Class 2.2; an overseas-marketed chemical-synthesis equivalent → overseas generic as Class 5.2, domestic as Class 3/4. The clarification may improve filing-path visibility for Chinese and international sponsors, although the appropriate route remains product-specific and should be confirmed with current CDE requirements. On the innovation side, ProteLight Pharma's 培来加南喷雾剂 (Pelaigan spray, brand 普亦克®) — a first-in-class antimicrobial peptide — won NMPA approval on 17 June 2026, reported by the cited source as the first approved cathelicidin-class anti-infective, targeting burn/wound secondary infections including drug-resistant Acinetobacter baumannii.
B2B implication: build a well-structured core CMC package (impurity control, characterisation, process validation) that satisfies EMA's June 2026 expectations and China's Class 2.2/3/4 logic, which may reduce duplicated preparation, while each authority's current requirements still need a separate gap assessment. The cited developments also make China relevant to partnership and competitive-intelligence reviews; supplier and product claims still require case-specific verification.
B2B buyer takeaways
- EMA's June 2026 peptide guideline + April 2026 CJEU ruling may clarify aspects of a potential generic pathway for chemically-synthesised peptides in Europe.
- China's CDE (Mar 2026) clarified chemical-synthesis peptide generic filing paths (Class 2.2 / 3 / 4 / 5.2) — plan CMC accordingly.
- A strong, impurity-focused core CMC package may support work across FDA, EMA and NMPA; perform a separate gap assessment for each authority.
- China is showing both regulatory development and product innovation; confirm reported first-in-class or first-in-market claims against primary records before reuse.
Sources & References
1. 南京肽业, "YM说多肽|新药研发中的多肽机遇:挑战、规则与未来十年" (EMA guideline, CJEU ruling, CDE) http://www.njpeptide.com/article/7841.html
2. 医药魔方 ByDrug, "国家药审中心明确化学合成多肽仿制药申报路径" (CDE Mar 2026) https://bydrug.pharmcube.com/news/detail/de135f6971934d299e4ae6d0bbbc9996
3. 中国高新网, "全球首款!江阴高新区企业自研新药获批上市" (ProteLight NMPA Jun 2026) http://www.chinahightech.com/yuanqu/2026-06/24/content_536555.html
4. 江阴网, "全球首款!江阴原创药获批上市!" (ProteLight 普亦克®) https://www.cnjsjy.cn/article?id=608517
Editorial summary of third-party reporting only; not legal, medical, investment or regulatory advice. Figures, market estimates and regulatory statements reflect the cited source and publication date, and should be rechecked for the relevant product, jurisdiction and intended use.